Literature DB >> 18855717

The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure.

Michel R Hoenig1, Cesario Bianchi, Anthony Rosenzweig, Frank W Sellke.   

Abstract

Recent studies revealed an exceedingly high mortality with diastolic heart failure that was previously regarded as relatively benign compared to systolic heart failure. Prominent risk factors for diastolic heart failure are increasing age, hypertension and diabetes. These risk factors are associated with coronary microvascular rarefaction and resultant decreased coronary flow reserve, thereby rendering the myocardium vulnerable to ischemia. We discuss the importance of angiogenic gene programming in preserving the coronary microvasculature, preserving cardiac function and altering disease course. Further, we discuss the possible utility of therapies that activate hypoxia inducible factor-1 in preventing rarefaction of the coronary microvasculature and maintaining cardiac diastolic function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855717     DOI: 10.2174/157016108785909779

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  33 in total

1.  Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival.

Authors:  Mandar S Joshi; Liyue Tong; Angela C Cook; Brandon L Schanbacher; Hong Huang; Bing Han; Leona W Ayers; John Anthony Bauer
Journal:  Cardiovasc Pathol       Date:  2012-01-28       Impact factor: 2.185

Review 2.  Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.

Authors:  Nadia Hedhli; Kerry Strong Russell
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

3.  Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects.

Authors:  Tamas Kiss; Cory B Giles; Stefano Tarantini; Andriy Yabluchanskiy; Priya Balasubramanian; Tripti Gautam; Tamas Csipo; Ádám Nyúl-Tóth; Agnes Lipecz; Csaba Szabo; Eszter Farkas; Jonathan D Wren; Anna Csiszar; Zoltan Ungvari
Journal:  Geroscience       Date:  2019-08-28       Impact factor: 7.713

Review 4.  ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4.

Authors:  Timothy D O'Connell; Robert C Block; Shue P Huang; Gregory C Shearer
Journal:  J Mol Cell Cardiol       Date:  2016-12-14       Impact factor: 5.000

5.  EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4.

Authors:  Julie A Eclov; Qingwen Qian; Rebecca Redetzke; Quanhai Chen; Steven C Wu; Chastity L Healy; Steven B Ortmeier; Erin Harmon; Gregory C Shearer; Timothy D O'Connell
Journal:  J Lipid Res       Date:  2015-10-04       Impact factor: 5.922

6.  Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging.

Authors:  S Jeson Sangaralingham; Denise M Heublein; Joseph P Grande; Alessandro Cataliotti; Andrew D Rule; Paul M McKie; Fernando L Martin; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-24

7.  Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion.

Authors:  Michael P Robich; Louis M Chu; Thomas A Burgess; Jun Feng; Cesario Bianchi; Frank W Sellke
Journal:  J Cardiovasc Pharmacol       Date:  2011-01       Impact factor: 3.105

8.  Heart failure with preserved vs reduced ejection fraction following cardiac rehabilitation: impact of endothelial function.

Authors:  Seiya Tanaka; Yoshihito Sanuki; Kiyoshi Ozumi; Takashi Harada; Hiromi Tasaki
Journal:  Heart Vessels       Date:  2018-02-01       Impact factor: 2.037

9.  Myocardial perfusion MRI shows impaired perfusion of the mouse hypertrophic left ventricle.

Authors:  Bastiaan J van Nierop; Bram F Coolen; Noortje A Bax; Wouter J R Dijk; Elza D van Deel; Dirk J Duncker; Klaas Nicolay; Gustav J Strijkers
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-28       Impact factor: 2.357

Review 10.  Renal toxicity of targeted therapies.

Authors:  Ronan J Kelly; Bertrand Billemont; Olivier Rixe
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.